Skip to Content
Morningstar

CureVac NV Ordinary Shares CVAC Stock Quote

Morningstar Rating
| Rating as of

Morningstar‘s Stock Analysis CVAC

Valuation
Currency in USD

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

CureVac Focuses on Expanding Pipeline Through Enhanced Oncology Strategy; $15.40 FVE Retained

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman |

CureVac is working to expand its pipeline by furthering its cancer vaccine capabilities. CureVac acquired Amsterdam-based Frame Cancer Therapeutics for EUR 32 million. Frame Cancer Therapeutics is a private company focused on identifying neoantigens across different cancer types. CureVac also established a partnership with Belgium-based myNEO to develop mRNA-based cancer vaccines using myNEO’s tumor antigen discovery platform. This acquisition and partnership help to enhance CureVac’s oncology capabilities, but it’s too soon to forecast the impact of these new platforms since they are in very early research and development phases.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CVAC

More

Company Profile CVAC

Business Description

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac’s first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company’s other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Contact
Friedrich-Miescher-Strasse 15
Tubingen, BW, 72076, Germany
T +49 707198830
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type —
Employees 900

Related News CVAC

Market Update

Markets Brief: Will the Fed Stay the Course or Step It Up on Rate Hikes?

FOMC meeting ahead; Chinese tech stocks jump, cruise line stocks sink.
Sandy Ward
Market Update

Markets Brief: The Fed's Favorite Inflation Indicator on Deck

Stocks avoid bear market, barely, as retailers get slammed.
Jakir Hossain
Stock Strategist Industry Reports

COVID-19 Vaccine Efficacy Solid Even as Delta Extends Pandemic

Hopes for eradication fade, further highlighting the benefits of vaccination and boosters.
Karen Andersen
Stock Strategist Industry Reports

Moderna Dominates COVID-19 Vaccine Manufacturers, at Least for Now

The global COVID-19 vaccine market is currently dominated by mRNA firms, but competitors are gaining strength.
Karen Andersen
Stock Strategist

Moderna's Innovation Still Building a Moat

The company's COVID-19 vaccine has shown the vast potential of its mRNA technology.
Karen Andersen
Stock Strategist Industry Reports

COVID-19 Vaccine Distribution and Herd Immunity to End Pandemic

Successful vaccine development and rollout will boost industry goodwill and reduce ESG risk, but we’re keeping our valuations steady.
Karen Andersen